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Survival rateAbstract Background: Patients with recurrent/metastatic head and neck squamous cell car-
cinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses
and limited therapeutic options. Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1)
are frequently upregulated in HNSCC. The international, multi-institutional, single-arm,
phase II HAWK study (NCT02207530) evaluated durvalumab monotherapy, an anti-PD-
L1 monoclonal antibody, in PD-L1-high patients with platinum-refractory R/M HNSCC.
Patients and methods: Immunotherapy-naı̈ve patients with confirmed PD-L1-high tumour cell
expression (defined as patients with 25% of tumour cells expressing PD-L1 [TC  25%] using
the VENTANA PD-L1 [SP263] Assay) received durvalumab 10 mg/kg intravenously every 2
weeks for up to 12 months. The primary end-point was objective response rate; secondary end-
points included progression-free survival (PFS) and overall survival (OS).
Results: Among evaluable patients (n Z 111), objective response rate was 16.2% (95% con-
fidence interval [CI], 9.9e24.4); 29.4% (95% CI, 15.1e47.5) for human papillomavirus
(HPV)-positive patients and 10.9% (95% CI, 4.5e21.3) for HPV-negative patients. Median
PFS and OS for treated patients (n Z 112) was 2.1 months (95% CI, 1.9e3.7) and 7.1 months
(95% CI, 4.9e9.9); PFS and OS at 12 months were 14.6% (95% CI, 8.5e22.1) and 33.6%
(95% CI, 24.8e42.7). Treatment-related adverse events were 57.1% (any grade) and 8.0%
(grade 3); none led to death. At data cut-off, 24.1% of patients remained on treatment
or in follow-up.
Conclusion: Durvalumab demonstrated antitumour activity with acceptable safety in PD-L1-
high patients with R/M HNSCC, supporting its ongoing evaluation in phase III trials in first-
and second-line settings. In an ad hoc analysis, HPV-positive patients had a numerically high-
er response rate and survival than HPV-negative patients.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recurrent/metastatic (R/M) head and neck squamous
cell carcinoma (HNSCC) has poor prognosis and low
survival rates [1]. Until recently, patients with progres-
sive disease (PD) after first-line combination chemo-
therapy and cetuximab were treated with
chemotherapeutic monotherapy, which yielded objective
response rates (ORRs) of 4e13% [2e5].
HNSCC tumours often exhibit T-cell infiltration and
can be antigenic due to high mutation burden or virally
associated antigens, yet often escape immune elimina-
tion through inhibition of antitumour T-cell responses
resulting from expression of checkpoint pathway com-
ponents, such as programmed cell death-ligand 1 (PD-
L1) [6,7]. Targeting the programmed cell death-1 (PD-
1)/PD-L1 pathway has resulted in clinically meaningful
activity and improved overall survival (OS) in patients
with previously treated R/M HNSCC [8e12]. In 2016, 2
immuno-oncology agents targeting PD-1 were approvedfor patients with previously treated R/M HNSCC with
PD on or after a platinum-based therapy [13,14].
Durvalumab is a selective, high-affinity, engineered
human IgG1 monoclonal antibody (mAb) that blocks
PD-L1 binding to PD-1 and CD80, allowing T-cells to
recognise and kill tumour cells (TC). Durvalumab has
shown antitumour activity in patients with HNSCC
[15,16]. In a phase I/II study that included 62 patients
with R/M HNSCC, ORR with durvalumab was 11% in
all patients, 18% in 22 patients with high PD-L1 expres-
sion (TC  25%) and 8% in 37 patients with PD-L1-low/
negative expression (TC< 25%) [16]. Encouraging 6- and
12-month OS rates of 62% and 42%, respectively, were
observed in this pre-treated population [16].
In this report, we present the safety and efficacy of
durvalumab from an international, multicentre study
(NCT02207530) in patients with R/M HNSCC with PD-
L1-high expression (TC  25%) after progression after
only 1 platinum-containing regimen given in the R/M
setting.
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2.1. Study design
In this single-arm, phase II trial, eligible patients
received 10 mg/kg durvalumab by intravenous infusion
every 2 weeks for up to 12 months or until confirmed
PD, initiation of alternative cancer therapy, unaccept-
able toxicity or consent withdrawal. The primary end-
point was ORR using blinded independent central re-
view (BICR) as measured by Response Evaluation
Criteria in Solid Tumors (RECIST) v1.1 guidelines. For
a complete or partial response, radiographic confirma-
tion was needed 4 weeks after first response. Second-
ary end-points were best objective response, duration of
response, time to response, disease control rate,
progression-free survival (PFS) and OS; safety and
tolerability; and impact of treatment on symptoms and
health-related quality of life (HRQoL) measures.
2.2. Patient population
Patients aged 18 years with histologically confirmed R/
M HNSCC (oral cavity, oropharynx, larynx or hypo-
pharynx) not amenable to therapy with curative intent
(surgery or radiation therapy with or without chemo-
therapy/biologic therapy) and with PD-L1-high
(TC  25%) expression were included. The PD-L1
TC  25% cut-off was chosen for its ability to
discriminate between responders and non-responders in
HNSCC [17,18]. Eligible patients had tumour progres-
sion or recurrence during or after treatment with only 1
platinum-based systemic regimen for R/M disease.
Further eligibility criteria are provided in the Appendix.
All patients provided written informed consent, and
any locally required authorisations were obtained from
patient/legal representatives before any protocol-related
procedures.
2.3. Study assessments
Tumour response was assessed by computed tomogra-
phy or magnetic resonance imaging every 8 weeks for
the first 48 weeks and then every 12 weeks until
confirmed PD. Tumour response (complete [CR], partial
[PR], stable disease [SD] or PD) was based on BICR
according to RECIST v1.1. Patients with CR, PR or SD
at 12 months entered follow-up. Upon progression at
any time, asymptomatic patients or those without
functional decline were permitted to restart durvalumab
for up to 12 further months.
PD-L1 expression levels of newly acquired or archival
tumour tissues (<3 years old) were assessed by immu-
nohistochemistry with the VENTANA PD-L1 (SP263)
Assay (Ventana Medical Systems, Inc., AZ).
Human papillomavirus (HPV) status was either
collected from historical medical records or based onassessment according to local standard procedures and
participating institutions’ individual standards; status
may have been measured by p16 immunohistochemistry,
fluorescence in situ hybridisation or polymerase chain
reaction.
Adverse events (AEs) were monitored every 2 weeks
for the first 8 weeks and then every 4 weeks and graded
according to National Cancer Institute CTCAE v4.03.
Safety monitoring continued for 90 d post-last dose.
Treatment-related AEs (TRAEs) of special interest
(AESIs) were defined as AEs associated with potential
inflammatory or immune-related events. A suspected
immune-mediated AE (imAE) was identified and
defined as an AESI that required the use of systemic
steroids or other immunosuppressants, and/or, for spe-
cific endocrine events, endocrine therapy. All pneumo-
nitis AEs were classified as suspected imAEs, regardless
of concomitant steroid use. Patient-reported outcomes
(PRO) assessments are presented in the Appendix.2.4. Statistical methods
The primary objective assessment was based on all
evaluable patients (evaluable analysis set), which
included all treated patients who had baseline tumour
assessments and measurable disease at baseline accord-
ing to BICR and was set to determine whether the lower
limit of the 95% confidence interval (CI) of ORR was
>13%. Secondary efficacy variables were analysed based
on evaluable analysis set and the full analysis set, which
included all treated patients. Distributions of PFS and
OS were estimated by KaplaneMeier method.
Data underlying the findings described in this study
may be obtained in accordance with AstraZeneca’s data
sharing policy described at https://astrazenecagroup
trials.pharmacm.com/ST/Submission/Disclosure.3. Results
3.1. Patient disposition and baseline characteristics
The data cut-off date was 31st March 2017, approxi-
mately 12 months after the last patient began treatment.
Of 112 patients treated, 111 were evaluable for efficacy
assessment; 1 patient did not have measurable disease at
baseline according to BICR (Fig. A.1). At data cut-off,
21 patients (18.8%) had completed 12 months of treat-
ment, and 27 (24.1%) remained on study on treatment or
in follow-up. Ninety-one patients (81.3%) discontinued
treatment: 69.6% due to PD, 7.1% due to AEs and 4.5%
due to patient decision.
Demographic and disease characteristics of patients
are shown in Table 1. Median age of patients was 60
years (range, 24e84 years), and 59.8% received prior
cetuximab. Most patients were either current or former
(n Z 69; 61.6%) smokers. Among 99 patients evaluable
Table 2
Treatment-related adverse events.a
Treatment-related adverse events Durvalumab (N Z 112)
n (%)















Decreased appetite 6 (5.4)




























Select hepatic events 9 (8.0)





Other rare/miscellaneous 3 (2.7)
AE, adverse event.
a As assessed by investigator.
Table 1
Patient disposition and baseline characteristics.
Patient disposition N
Patients screened, na 158
Patients who failed screening, n 46
Patients receiving durvalumab, n (%)b 112 (100)
Evaluable patients, nc 111
Patients completing 12 months of treatment, n (%) 21 (18.8)
Patients who discontinued therapy, n (%) 91 (81.3)
Progression, n (%) 78 (69.6)
Baseline characteristicsb N Z 112
Median age, years (range) 60 (24e84)
Male, n (%) 80 (71.4)
ECOG PS, n (%)d
0 34 (30.4)
1 77 (68.8)
Classification at study enrolment, n (%)
Locoregional recurrence 39 (34.8)
Metastatic diseasee 73 (65.2)
Primary tumour location





PD-L1 positive 112 (100)
Smoking/nicotine status, n 102
Current, n (%) 10 (8.9)
Former, n (%) 59 (52.7)
Never, n (%) 43 (38.4)
HPV/p16 status, nf 99
Positive, n (%) 34 (34.3)
Oropharynx 20 (58.8)
Oral cavity 7 (20.6)
Hypopharynx 2 (5.9)
Larynx 5 (14.7)
Negative, n (%) 65 (65.7)
Oropharynx 17 (26.2)




Prior cetuximab, n (%) 67 (59.8)
ECOG PS, European Cooperative Oncology Group performance
status; HPV, human papillomavirus; PD-L1, programmed cell death-
ligand 1.
a Informed consent.
b Full analysis set, n Z 112.
c One patient did not have measurable disease at baseline according
to blinded independent central review.
d One missing evaluation.
e One patient had both locoregional recurrence and metastatic
disease.
f HPV/p16 status was collected regardless of tumour site. Sites
outside of oropharynx were tested.
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(65.7%) were negative. Oropharynx was the primary site
in most (59%) HPV-positive tumours.
3.2. Safety
Median duration of durvalumab treatment was 3.5
months (range, 0.3e12.2). Nine patients had TRAEsleading to dose interruptions of durvalumab. One pa-
tient discontinued treatment due to grade 4 pneumo-
nitis, grade 3 hepatitis and grade 2 nephritis, all of which
were considered related to durvalumab; this patient later
died due to PD. There were no TRAEs leading to death.
Most AEs were mild to moderate (grade 1 or 2). Alto-
gether, 64 patients (57.1%) reported at least 1 TRAE
(Table 2). Grade 3/4 TRAEs occurred in 9 patients, of
which 2.7% had increased gamma-glutamyltransferase.
AESIs occurred in 39 patients: skin related (15.1%),
endocrine related (12.5%), renal/hepatic related (10.7%),
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other (2.7%) (Table 2). imAEs were observed in 18 pa-
tients treated with durvalumab; the majority were grade
1/2 (hypothyroidism [11 patients], select hepatic events
and hyperthyroidism [2 each], diarrhoea, select renal
events and rash [1 each]). Four patients had pneumo-
nitis, 1 of which was grade 3.
3.3. Efficacy
Eighteen patients treated with durvalumab had a
response (ORR, 16.2%; 95% CI, 9.9e24.4) (Table 3),
including 1 CR (0.9%) and 17 PR (15.3%). Three pa-
tients (2.7%) had an unconfirmed CR/PR. Disease
control rate (CR þ PR þ SD) at 24 weeks was 23.4%,
and 58 patients (52.3%) had PD during the first 12
months of treatment. Median time to response was 2.0
months (range, 1.6e9.2). At data cut-off, median
duration of response was estimated to be 10.3 months
and 10 of 18 patients (55.6%) had ongoing responses.
Decreases in size of target lesions occurred in 40.5% of
all patients (Fig. A.2). ORR was consistent across
most subgroups evaluated, with the exception of HPV
status.
In an exploratory analysis testing HPV/p16 at all
anatomical sites (i.e. not limited to oropharynx), ORR
among 34 patients with HPV-positive tumours was
29.4% (95% CI, 15.1e47.5) and 10.8% (95% CI,Table 3
Best objective response rate with durvalumab treatment.






Complete response 1 (0.9)
Partial response 17 (15.3)
Stable disease 7 (6.3)
Unconfirmed complete/partial response 3 (2.7)
Progressive disease 58 (52.3)
Median time to response, months (range) 2.0 (1.6e9.2)
Median duration of response, months 10.3
ORR by HPV/p16 status, n (%)




Oropharynx (n Z 20) 6 (30.0)
Non-oropharynx (n Z 14) 4 (28.6)
Oral cavity (n Z 7) 1 (14.3)
Larynx (n Z 5) 2 (40.0)
Hypopharynx (n Z 2) 1 (50.0)




Oropharynx (n Z 17) 2 (11.8)
Non-oropharynx (n Z 48) 5 (10.4)
Oral cavity (n Z 33) 3 (9.1)
Hypopharynx (n Z 6) 1 (16.7)
Larynx (n Z 8) 1 (12.5)
Other (n Z 1) 0 (0)
CI, confidence interval; HPV, human papillomavirus; ORR, objective
response rate.4.4e20.9) among 65 patients with HPV-negative tu-
mours (Table 3). Among patients with HPV-positive
tumours, ORR with durvalumab was 30% (95% CI,
11.9e54.3) for oropharyngeal primary site and 28.6%
(95% CI, 8.4e58.1) for non-oropharyngeal site.
Among patients with HPV-negative cancer, ORR was
11.8% (95% CI, 1.5e36.4) for oropharyngeal site and
10.4% (95% CI, 3.5e22.7) for non-oropharyngeal site
(Table 3).
KaplaneMeier estimate of median PFS was 2.1
months (95% CI, 1.9e3.7) (Fig. 1A). PFS at 6, 12 and 18
months was 25.5% (95% CI, 17.6e34.1), 14.6% (95% CI,
8.5e22.1) and 8.7% (95% CI, 2.7e19.2), respectively.
Median PFS in patients with HPV-positive and HPV-
negative tumours was 3.6 months (95% CI, 1.9e5.6)
versus 1.8 months (95% CI, 1.6e2.0), respectively.
At median follow-up of 6.1 months (range, 0.2e24.3),
median OS was 7.1 months (95% CI, 4.9e9.9) (Fig. 1B).
OS at 12 and 18 months was 33.6% (95% CI, 24.8e42.7)
and 23.0% (95% CI, 14.3e32.9), respectively. At data
cut-off, 27 patients (24.1%) remained on study treatment
or in follow-up without progression. KaplaneMeier
estimate of median OS in patients with HPV-positive
and HPV-negative tumours was 10.2 months (95% CI,
7.2e16.3) versus 5.0 months (95% CI, 3.4e8.4),
respectively (Fig. 1C).
3.4. Patient-reported outcomes in symptoms and HRQoL
Based on the European Organisation for Research and
Treatment of Cancer (EORTC) 30-item core QoL
questionnaire (QLQ-C30), PROs were improved over
baseline for several measures (Fig. 2A). Clinically
meaningful improvements, defined as an increase in
baseline score of 10 at 2 consecutive assessments 14
d apart, were observed for global health status/QoL
(13.5%; 95% CI, 8.1e21.8), physical functioning (17.1%;
95% CI, 10.1e27.6) and fatigue (21.3%; 95% CI,
14.1e31.0) (Table A.1). To note, increased scores on the
global health status and functioning scales indicate
better health status/function. Median time to deterio-
ration was 3.7 months for global health status/QoL, 5.0
months for physical functioning and 1.8 months for
fatigue.
Head and neck cancerespecific symptoms evaluated
using the EORTC QoL questionnaire head and neck
cancer module (QLQ-H&N35) (Fig. 2B) showed clini-
cally meaningful improvements, defined as a decrease in
baseline score of 10 at 2 consecutive assessments 14
d apart, for mouth pain (24.6%; 95% CI, 16.0e36.0),
swallowing (19.4%; 95% CI, 11.4e30.9), taste and smell
(34.3%; 95% CI, 24.1e46.3) and speech (28.4%; 95% CI,
19.7e39.0) (Table A.2). To note, decreased scores on
symptom scales represent symptom improvement. Me-
dian time to deterioration was 4.6 months for mouth
pain, 4.9 months for swallowing, 4.9 months for taste
and smell and 2.7 months for speech.
Fig. 1. KaplaneMeier estimates of PFS (A) and OS (B). Exploratory analysis of KaplaneMeier estimates of OS by HPV status (C). HPV
status was unknown for 13 patients (full analysis set; NZ 112). CI, confidence interval; HPV, human papillomavirus; OS, overall survival;
PFS, progression-free survival.
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4.1. Conclusions
Durvalumab demonstrated clinically meaningful anti-
tumour activity in patients with HNSCC with PD-L1-
high expression (TC  25%) who had progressed after
first-line platinum-based therapy in the R/M setting.
ORR was 16.2% (95% CI, 9.9e24.4), with over half of
patients (55.6%) maintaining their response at data cut-
off. A median OS of 7.1 months was observed, with
approximately one-third (33.6%) of patients surviving
1 year. In an ad hoc analysis, HPV-positive patients
with HPV-positive tumours had a numerically higher
ORR and OS than patients with HPV-negative
tumours.
Durvalumab exhibited a manageable safety profile,
consistent with previous reports [16,19]. While most
patients (57.1%) reported at least 1 TRAE, most were
grade 1/2, with grade 3/4 TRAEs occurring in 8.0% ofFig. 2. Patient-reported outcomes assessed by EORTC QLQ-C30 v3
analysis set; N Z 112) (B). Error bars represent 95% CI for the mean
Organisation for Research and Treatment of Cancer; QLQ-C30, 30-ite
and neck cancer module; QoL, quality of life.patients. There were no deaths due to TRAEs, and only
1 patient discontinued durvalumab because of a TRAE.
Finally, improvements in PROs measured by both
EORTC QLQ-C30 and QLQ-H&N35 scales were
observed with durvalumab treatment, suggesting
improved QoL for patients.
4.2. Discussion
To our knowledge, this is the first large prospective
study evaluating an anti-PD-L1 mAb in patients with R/
M HNSCC. While direct comparison to CHECK-
MATE 141 or KEYNOTE-040 phase III studies is
limited based on differences in study design and inclu-
sion criteria, including PD-L1 expression, it is important
to note that, despite an ORR of 13.3% (95% CI,
9.3e18.3) in CHECKMATE 141, nivolumab improved
OS compared with standard-of-care therapy (hazard
ratio, 0.70; 97.73% CI, 0.51e0.96, p Z 0.01) [10,12].
This is similar to other second-line trials in advanced(full analysis set; N Z 112) (A) and EORTC QLQ-H&N35 (full
change from baseline. CI, confidence interval; EORTC, European
m core QoL questionnaire; QLQ-H&N35, QoL questionnaire head
Fig. 2. (continued).
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low response rates, treatment with single-agent anti-PD-
1 or PD-L1 mAbs led to significant OS improvement
compared with traditional chemotherapy [19]. The sta-
tistical threshold of 95% CI for ORR was set at >13% in
this study. Although the lower limit for ORR was only
9.9%, promising OS was observed with durvalumab in
this platinum-pre-treated patient population.
The ad hoc exploratory analysis showed that among
this PD-L1-high cohort, patients with HPV/p16-positive
tumours (all tumour locations) treated with durvalumab
experienced higher response rates and longer survival
than patients with HPV-negative tumours. Conflicting
results have been observed as to whether patients with
HPV-positive tumours have improved efficacy with
blockade of the PD-1/PD-L1 pathway [9e11]; however,
it is important to consider both PD-L1 expression and
HPV status together, given PD-L1 expression can be
predictive of efficacy. While analysis of KEYNOTE-055
with pembrolizumab showed similar ORR by HPV
status, this analysis included both PD-L1-negative and
PD-L1-positive patients [9]. Similar to our results,patients with HPV-positive tumours had higher ORR
and longer OS in KEYNOTE-012, where all patients
were PD-L1 positive (TC  1%) [9,11]. In an explor-
atory subgroup analysis of PD-L1-negative patients
treated with nivolumab in CHECKMATE 141, patients
with HPV-positive tumours had median OS of 10
months versus 7.1 months for those with HPV-negative
tumours [10]. It is possible that virally associated
tumour antigenicity in combination with intratumoural
inflammation is predictive of response. Further research
is needed to determine whether HPV is independently
associated with improved treatment outcomes with anti-
PD-1 or anti-PD-L1 mAbs.
In this study, non-oropharyngeal cancer patients
were included in the exploratory analysis of HPV status.
Interestingly, while HPV does not have a consistent or
established role in oncogenesis or prognosis of non-
oropharyngeal sites, the response rate of non-
oropharyngeal HPV-positive tumours was similar to
that of oropharyngeal HPV-positive tumours. Together,
all patients with HPV-positive tumours still had doubled
median OS compared with HPV-negative tumours.
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needed to determine whether HPV was biologically
relevant in these non-oropharyngeal patients, or
whether the presence of HPV in non-oropharyngeal
primary tumours has any immunologic effect that might
lead to better efficacy.
Finally, HNSCC patients in whom toxicity from
disease and treatment can often lead to long-term
impairment, disability and handicap, showed improve-
ments in HRQoL assessments. The impact of durvalu-
mab versus standard-of-care chemotherapy on patient
QoL will be assessed in 2 randomised phase III trials
[20,21].
This study has 2 design features that warrant careful
interpretation of its results. First, as a non-randomised
single-arm study, it lacks a standard-of-care control
arm. Second, the patient population had only PD-L1-
high-expressing tumours, compared with earlier studies
of patients with tumours of PD-L1-high and PD-L1-
low/negative status; the absence of PD-L1-low/negative
tumours allowed focused analysis on this particular
subgroup of patients that may be more likely to respond
to anti-PD-L1 mAb therapy. A companion phase II
study, CONDOR, has assessed responses to durvalu-
mab monotherapy in a PD-L1-low/negative HNSCC
population (NCT02319044) [22]. The variety of tech-
nologies, assays and cut-off algorithms used to deter-
mine PD-L1 expression make comparisons across
different trials challenging. Another limitation is that
HPV status was determined by different methods at the
discretion of each participating site.
Overall, encouraging efficacy was observed with
single-agent durvalumab in PD-L1-high R/M HNSCC
patients, most of whom had failed cetuximab in addition
to platinum-based chemotherapy. Currently, 2 ongoing
phase III trials (EAGLE NCT02369874; KESTREL
NCT02551159) will evaluate durvalumab with or
without tremelimumab in patients in the first- and
second-line settings for R/M HNSCC [20,21].
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